Journal September 15, 2026 7 min read

Tirzepatide: sourcing, documentation and price

A research-supply overview of tirzepatide: identifiers, receptor targets, current study landscape, documentation expectations and pricing factors for laboratory use.

peptides-pro Editorial

Tirzepatide is a synthetic peptide dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is supplied for laboratory research as a lyophilised powder, typically as the free base or an acetate salt, and is not intended for human or veterinary use. The compound is also known by the research code LY3298176 and is described in the literature as a GIP/GLP-1 receptor agonist (RA) [6]. Identifiers such as sequence, molecular formula and molecular weight are not provided in the evidence block for this page; researchers should obtain those from the certificate of analysis accompanying each lot.

The work described below centres on the GIP and GLP-1 receptor families and their downstream effects on gastric emptying, postprandial glycaemia, body weight and metabolic parameters.

Research Studies

Tirzepatide and preoperative weight loss before one anastomosis gastric bypass

A registered clinical trial compares three preoperative strategies before one anastomosis gastric bypass (OAGB) for severe obesity: tirzepatide for 60 days, a ketogenic diet for 4 weeks, or standard care [1]. The primary outcome is weight loss one year after surgery; secondary outcomes include safety, surgical outcomes and improvement in obesity-related conditions such as diabetes, high blood pressure and sleep apnea [1]. This is a human study and is ongoing; no results are reported in the evidence block.

Tirzepatide and progestin intrauterine device in endometrial hyperplasia and grade 1 endometrial cancer

A phase II trial studies whether adding tirzepatide injections to a levonorgestrel intrauterine device (LNG-IUD) improves pathologic response — the absence of cancer cells in tissue samples after treatment — in women with endometrial atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) or grade 1 endometrial cancer who are overweight or obese [2]. The evidence notes that endometrial cancer occurrence has continued to rise in the United States and that over half of cases are thought to be attributable to being overweight and obese, with a weight-dependent risk relationship [2]. AH/EIN is described as a precancerous condition of the endometrium [2].

Tirzepatide and levonorgestrel IUD therapy for EIN and early-stage endometrial cancer

A separate single-arm study evaluates the feasibility, safety and preliminary efficacy of tirzepatide in combination with standard LNG-IUD therapy in patients with endometrial intraepithelial neoplasia (EIN) or grade 1 endometrioid endometrial carcinoma with co-existing obesity and metabolic risk factors [3]. Participants receive tirzepatide once weekly while continuing standard clinical management with an LNG-IUD; treatment decisions remain at the discretion of the treating physician [3]. The primary objective is pathologic response at approximately 6 months, with secondary objectives including changes in metabolic parameters [3].

Tirzepatide and real-world outcomes in Pakistani adults with obesity, prediabetes and type 2 diabetes

A multicentre, prospective, observational study follows 330 adults starting tirzepatide as part of routine clinical care across ten diabetes and endocrinology centres in Pakistan [4]. All participants have obesity and are grouped into three cohorts based on blood sugar status at the start: obesity without diabetes, prediabetes with obesity, and type 2 diabetes [4]. The stated aim is to address the lack of information on how tirzepatide works for people in South Asia, and none from Pakistan specifically [4].

Tirzepatide and central centrifugal cicatricial alopecia

A pilot clinical trial investigates whether tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults [5]. The main questions are whether tirzepatide improves the symptoms and signs of active CCCA, whether it changes the activity of genes in the scalp — especially genes related to scarring — and whether it promotes hair regrowth [5]. Participants inject tirzepatide once a week for 12 months, attend clinic visits for scalp examinations and photographs, have scalp biopsies at the beginning of the study and after 6 months of treatment, and undergo blood tests [5].

Tirzepatide and postbariatric hypoglycemia after Roux-en-Y gastric bypass

A case series describes 3 patients with postbariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass who were treated with tirzepatide [6]. All patients presented with symptomatic hypoglycemia characterised by episodes of diaphoresis, visual disturbances, confusion and documented low blood glucose levels occurring postprandially [6]. Conventional management strategies, including dietary modifications, acarbose and other pharmacotherapies, were either partially effective or limited by side effects [6]. The evidence block does not report the outcome of tirzepatide initiation in these cases.

Tirzepatide and bowel frequency in ileal pouch-anal anastomosis

A clinical trial investigates whether tirzepatide (Zepbound) can decrease bowel frequency in patients who have an ileal pouch-anal anastomosis (IPAA or pouch) better than standard-of-care anti-diarrheal therapy [7]. Participants visit the clinic 5 times, answer daily symptom questions, take the study product as instructed and provide a stool sample 4 times [7]. This is a human study and is ongoing; no results are reported in the evidence block.

Tirzepatide and stomach emptying in type 1 diabetes with overweight or obesity

A study of tirzepatide (LY3298176) in participants with type 1 diabetes mellitus (T1DM) and overweight or obesity aims to learn more about how tirzepatide affects stomach emptying [8]. Participation lasts about 8 weeks, including screening and follow-up [8]. This is a human study and is ongoing; no results are reported in the evidence block.

Tirzepatide and comparative effectiveness in type 2 diabetes with cardiovascular disease

A comment on a comparative-effectiveness analysis of tirzepatide versus dulaglutide or semaglutide on major cardiovascular events in type 2 diabetes and cardiovascular disease is listed as reference-only material [12]. The evidence block does not provide the findings of that analysis; researchers should consult the original publication for details.

Tirzepatide and weight regain after discontinuation

A reconstructed aggregate-data Bayesian longitudinal meta-analysis estimated post-discontinuation weight-regain trajectories for semaglutide and tirzepatide and explored predictors of faster regain [11]. The evidence block provides only the background and objective of that analysis; the estimated trajectories are not reproduced here. Researchers should consult the original publication for the numerical results.

Tirzepatide and oral health implications

A reference-only article discusses emerging oral health implications of tirzepatide for oral medicine practice [9]. The evidence block does not provide the specific findings; researchers should consult the original publication.

Tirzepatide and glycaemic control in early uncontrolled type 2 diabetes

A reference-only item reports that in adults with early uncontrolled type 2 diabetes, tirzepatide versus intensified conventional care reduced HbA1c levels and weight at 2 years [10]. The evidence block does not provide the numerical values; researchers should consult the original publication.

Documentation and sourcing

For laboratory research, tirzepatide is typically supplied with a certificate of analysis (CoA) that states the lot-specific identity, purity and peptide content. Because the evidence block for this page does not provide sequence, molecular formula or molecular weight, researchers should rely on the CoA and, where available, an independent analytical method such as mass spectrometry or HPLC. The studies cited above are clinical investigations in human populations; they do not establish the identity, purity or suitability of any particular research-supply lot.

Price factors

Pricing for research-supply tirzepatide is not standardised and depends on factors such as lot size, purity grade, salt form, packaging and the documentation provided. The evidence block does not contain price data, and no price is quoted here. Researchers should request a current quotation and CoA from the supplier for the specific lot under consideration.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.